Home・Lista de Ações・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Abrir

14.53 3.42

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.04

Máximo

14.68

Indicadores-chave
By Trading Economics
Rendimento	-4.3M -18M
EPS	-0.19
Funcionários	37
EBITDA	-5.3M -17M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+109.37% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	130M 1.3B
Abertura anterior	11.11
Fecho anterior	14.53

Corvus Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de ago. de 2026, 23:56 UTC

Community Healthcare Trust Inc. shares are lower in after-market hours amid broader market caution related to geopolitical tensions and new U.S.-Iran sanctions.

24 de ago. de 2026, 23:56 UTC

Ares Capital Corp shares are trading roughly flat in after-hours. The stock remains above its 20-day moving average amid broader market caution.

24 de ago. de 2026, 23:56 UTC

Social Media

DICK'S Sporting Goods shares are higher in after-market trading as investors await earnings announcement tomorrow, despite earlier pulling back from a session high.

24 de ago. de 2026, 23:56 UTC

Dillard's Inc shares are lower in after-market hours amid cautious market sentiment influenced by geopolitical tensions and economic concerns.

24 de ago. de 2026, 23:56 UTC

Axon Enterprise Inc. shares advanced in after-market trading, following a higher close on Monday amid heightened market caution regarding U.S.-Iran relations and new sanctions.

24 de ago. de 2026, 23:56 UTC

Dycom Industries Inc shares are higher in after-market trading, reflecting a positive shift after five consecutive sessions of lower closes.

24 de ago. de 2026, 23:56 UTC

Vontier Corp shares traded roughly flat in after-market hours, remaining within a routine range since Monday's close.

24 de ago. de 2026, 23:56 UTC

Resmed Inc. shares are lower in after-market hours amid weak trading sentiment. No specific company news was identified to explain the decline.

24 de ago. de 2026, 23:56 UTC

Morgan Stanley shares are higher in after-market trading following Monday's close. The stock reached a session high earlier in the session.

24 de ago. de 2026, 23:56 UTC

Kanzhun Ltd shares increased in after-market trading, despite no specific news. Investor caution remains amid concerns over U.S.-Iran relations and economic implications.

24 de ago. de 2026, 23:56 UTC

Gogo Inc. shares are lower in after-market trading, continuing a decline since Monday amid broader market caution over geopolitical tensions and oil supply concerns.

24 de ago. de 2026, 23:56 UTC

Textron Inc shares are lower in after-market hours amid broader market caution linked to U.S.-Iran tensions and new sanctions affecting oil supply.

24 de ago. de 2026, 23:56 UTC

Dominion Energy shares are higher in after-market trading, reflecting a modest increase since Monday's close. The stock remains below its 20-day moving average.

24 de ago. de 2026, 23:56 UTC

Chipotle Mexican Grill Inc shares are lower in after-market hours amid broader market caution linked to geopolitical tensions and new sanctions affecting economic conditions.

24 de ago. de 2026, 23:56 UTC

Mid-America Apartment Communities shares are lower in after-market hours, reflecting notable volatility amid cautious broader market sentiment over geopolitical tensions.

24 de ago. de 2026, 23:56 UTC

Kulicke and Soffa Industries shares are higher in after-market hours, reflecting positive movement since Monday's close amid broader market caution.

24 de ago. de 2026, 23:56 UTC

Watsco Inc. shares are lower in after-market trading, continuing a trend of four consecutive daily declines and remaining below the 20-day moving average.

24 de ago. de 2026, 23:56 UTC

NRG Energy Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing investor sentiment amid concerns over U.S.-Iran relations.

24 de ago. de 2026, 23:56 UTC

Markel Group Inc. shares declined in after-market trading amid broader market caution related to geopolitical tensions and new sanctions, now 2.90% below its 20-day moving average.

24 de ago. de 2026, 23:56 UTC

Match Group Inc shares are lower in after-market trading. Broader market caution persists amid concerns over U.S.-Iran relations and oil supply disruptions.

24 de ago. de 2026, 23:56 UTC

General Mills Inc shares are lower in after-market hours, reflecting volatility amid broader market caution over U.S.-Iran relations and potential oil supply disruptions.

24 de ago. de 2026, 23:56 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower amid market caution over U.S.-Iran tensions and new sanctions impacting oil supply concerns.

24 de ago. de 2026, 23:52 UTC

APA Corp. shares are trading higher in after-market hours, reflecting a routine move. The stock has seen notable gains over the past month.

24 de ago. de 2026, 23:51 UTC

Hyatt Hotels Corp shares are lower in after-market hours, following a notable dip earlier amid volatility in U.S. Treasury yields and inflation concerns.

24 de ago. de 2026, 23:51 UTC

HP Inc. shares are lower in after-market hours, reversing a recent trend of higher daily closes despite an earlier rebound from session lows.

24 de ago. de 2026, 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, declining from earlier session peaks amid no specific news or developments.

24 de ago. de 2026, 23:51 UTC

ArcBest Corp shares are lower in after-market hours, continuing weak trading conditions. The stock remains below its 20-day moving average and near recent lows.

24 de ago. de 2026, 23:51 UTC

PENN Entertainment Inc shares are higher in after-market trading, despite remaining near the lower end of their one-month range and below the 20-day moving average.

24 de ago. de 2026, 23:51 UTC

Correlated Moves

Social Media

SPDR Gold Shares are higher in after-market hours, continuing a recent upward trend amid mixed global equity indices and rising silver prices.

24 de ago. de 2026, 23:51 UTC

Deluxe Corp's shares are lower in after-market trading, reflecting weaker performance below its 20-day moving average and near the lower end of its one-month range.

Comparação entre Pares

Variação de preço

Corvus Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

109.37% parte superior

Previsão para 12 meses

Média 29.5 USD 109.37%

Máximo 33 USD

Mínimo 27 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

Comprar

Manter

Vender

Com base em 4 analistas que deram avaliações de ações para Corvus Pharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.